The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression
Authors
Keywords
-
Journal
OncoImmunology
Volume -, Issue -, Pages e1457602
Publisher
Informa UK Limited
Online
2018-03-28
DOI
10.1080/2162402x.2018.1457602
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy
- (2018) Elisa Melucci et al. Journal of Translational Medicine
- DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy
- (2017) Livia Ronchetti et al. INTERNATIONAL JOURNAL OF CANCER
- A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer
- (2017) Thomas Wehler et al. LUNG CANCER
- Prognostic significance of PD-L1 in solid tumor
- (2017) Qianqian Wang et al. MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- (2017) Kent W. Mouw et al. Cancer Discovery
- Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients
- (2017) Xiaofang Xing et al. OncoImmunology
- PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
- (2017) Lihu Gu et al. PLoS One
- Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
- (2016) Christine Böger et al. Oncotarget
- The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients
- (2016) Minghui Zhang et al. Scientific Reports
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- ATM and ATR as therapeutic targets in cancer
- (2015) Anika Maria Weber et al. PHARMACOLOGY & THERAPEUTICS
- ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
- (2015) J. Shen et al. Cancer Discovery
- SWI/SNF Factors Required for Cellular Resistance to DNA Damage Include ARID1A and ARID1B and Show Interdependent Protein Stability
- (2014) R. Watanabe et al. CANCER RESEARCH
- Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer
- (2014) Jin Won Kim et al. Gastric Cancer
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Repair of Oxidative DNA Damage and Cancer: Recent Progress in DNA Base Excision Repair
- (2013) Timothy L. Scott et al. ANTIOXIDANTS & REDOX SIGNALING
- WEE1 inhibition and genomic instability in cancer
- (2013) Lianne E.M. Vriend et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer
- (2013) Luigi Di Lauro et al. Gastric Cancer
- Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy
- (2012) M. Maugeri-Saccà et al. CANCER TREATMENT REVIEWS
- Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
- (2009) Luigi Di Lauro et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now